Prevalence of asthma has increased considerably in recent decades throughout the world especially in developed countries. Airway inflammation is thought to be prime cause for repeated episodes of airway obstruction in asthmatics. Several studies have shown that reactive oxygen species (ROS) play a key role in initiation as well as amplification of inflammation in asthmatic airways. Excessive ROS production in asthma leads to alteration in key enzymatic as well as nonenzymatic antioxidants such as glutathione, vitamins C and E, beta-carotene, uric acid, thioredoxin, superoxide dismutases, catalase, and glutathione peroxidases leading to oxidant-antioxidant imbalance in airways. Oxidant-antioxidant imbalance leads to pathophysiological effects associated with asthma such as vascular permeability, mucus hypersecretion, smooth muscle contraction, and epithelial shedding. Epidemiological data also support the scientific evidence of oxidant-antioxidant imbalance in asthmatics. Therefore, the supplementation of antioxidants to boost the endogenous antioxidants or scavenge excessive ROS production could be utilized to dampen/prevent the inflammatory response in asthma by restoring oxidant-antioxidant balance. This review summarizes the scientific and epidemiological evidence linking asthma with oxidant-antioxidant imbalance and possible antioxidant strategies that can be used therapeutically for better management of asthma.
Introduction
Asthma is a lung disease characterized by inflammation and airway hyperresponsiveness. The pathogenesis of asthma involves persistent expression of a broad array of mediators from various inflammatory cells leading to secretion of bronchoconstrictive, pro-inflammatory, and chemoattractive mediators such as cysteinyl leukotrienes, reactive oxygen species (ROS), and cytokines [Andreadis et al. 2003 ; Barnes and Drazen, 2002; Henricks and Nijkamps, 2001] .
ROS can influence airway cells and reproduce many of the pathophysiologic features associated with asthma by initiating lipid peroxidation, altering protein structure, enhancing release of arachidonic acid from cell membranes, contracting (directly and indirectly) airway smooth muscle, increasing airway reactivity and airway secretions, increasing vascular permeability, increasing the synthesis and release of chemoattractants, inducing the release of tachykinins and neurokinins, decreasing cholinesterase and neutral endopeptidase activities, and impairing the responsiveness of -adrenergic receptors [Rahman and MacNee, 2002; Barnes et al. 1998; Barnes, 1994] .
The lungs have several natural antioxidant mechanisms to neutralize the effect of oxidants, which include enzymatic as well as nonenzymatic antioxidants. Enzymatic antioxidants include catalase, glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) and nonenzymatic antioxidants are vitamin E, vitamin C, albumin, uric acid, ceruloplasmin, and glutathione (GSH) [Heffner and Repine,1989; Van Asbeck et al. 1985; Toth et al. 1984] . These antioxidant defense systems form a tightly regulated antioxidant network to resist any change in the redox environment of intra-as well as extracellular space [Chaudiere and Ferrari-Iliou, 1999] . The inflammatory process results in oxidative stress that overwhelms endogenous antioxidants leading to tissue injury and asthma symptomatology. The use of antioxidants to boost the endogenous antioxidant system could be used to redress this imbalance leading to attenuation of severity and chronicity of the inflammatory response in asthma.
This review summarizes the existing literature on the role of oxidants and antioxidants in asthma and epidemiological studies showing the association between atopy/asthma and antioxidants. Further, it highlights the importance of potential antioxidants, which could be used as therapeutic supplementation for better management of asthma.
Sources of oxidants in the normal lung
Formation of ROS takes place constantly in every cell during normal metabolic processes. Cellular sites for production of ROS include mitochondria, microsomes, and enzymes (e.g., xanthine oxidase, P450 mono-oxygenase, cyclo-oxygenase, lipoxygenase, indole amine dioxygenase, monoamine oxidase). Under physiological conditions, the mitochondria are major intracellular sites of superoxide generation [Halliwell and Cross, 1994] . A potential source for the generation of microbicidal and/or pathological levels of superoxide (O 2 . À ) is the NADPH oxidase, which is found in neutrophils, eosinophils, monocytes, and macrophages [Babior, 1999; Conner and Grisham 1996] . Most of the O 2 . À generated in vivo undergoes a nonenzymatic or SOD-catalyzed reaction resulting in its dismutation into hydrogen peroxide (H 2 O 2 ) [McCord and Fridovich, 1969] . However, H 2 O 2 can also be directly produced by several oxidase enzymes including xanthine oxidase, monoamine, and amino acid oxidase [Halliwell and Cross, 1994; Janssen et al. 1993] . Once formed, the oxidizing potential of H 2 O 2 may be amplified by eosinophil-and neutrophilderived peroxidases, eosinophil peroxidase (EPO), and myeloperoxidase (MPO), respectively, which are important in host defense against parasites and pathogens. EPO and MPO are members of the mammalian peroxidase superfamily, which also includes lactoperoxidase, thyroid peroxidase, and prostaglandin H synthase, all of which share a high degree of structural and sequence similarity and rely on peroxide as the major source of oxidizing equivalents for catalysis [Andreadis et al. 2003 ].
Nitric oxide (NO), another free radical is produced by a wide variety of resident and inflammatory cells in the respiratory system [Ricciardolo et al. 2004] . NO is a short-lived free radical whose production is catalyzed by the enzyme nitric oxide synthase (NOS) . NO itself is generated via a five-electron oxidation of terminal guanidinium nitrogen on the aminoacid L-arginine. This reaction is catalyzed by NOS, which exists in three distinct isoforms: 1) constitutive neural NOS (NOS-I or nNOS); 2) inducible NOS (NOS-II or iNOS); 3) constitutive endothelial NOS (NOS-III or eNOS) [Ricciardolo et al. 2004] . All the three NOS isoforms are localized in the respiratory system and may co-operatively regulate various functions in the respiratory tract from bronchomotor tone to immunologic/ inflammatory responses. NO appears to have a role in smooth muscle relaxation by increasing the formation of cyclic guanyl monophosphate [Moncada and Higgs, 1993] , and in this way may regulate bronchomotor tone of the airways under normal physiological conditions.
ROS production and oxidative stress in asthma
Over the past decade, a number of studies have clearly demonstrated that (a) oxidative stress is an important consequence of the inflammatory response in asthma [Nadeem et al. 2005 [Nadeem et al. , 2003 Wood et al. 2003 ], (b) oxidative stress is associated with an alteration in antioxidant activity in the lung and blood [Sackesen et al. 2008; Nadeem et al. 2005 Nadeem et al. , 2003 Heffner and Repine, 1989] , and (c) oxidative stress is associated with the development of airway hyperresponsiveness [Saleh et al. 1998; Katsumata et al. 1990 ]. This is supported by the studies that have shown that inflammatory cells from peripheral blood and bronchoalveolar lavage (BAL) fluid of asthmatic subjects generate more superoxide anion radicals than those from controls [Nadeem et al. 2003; Cluzel et al. 1987] , exhaled air of patients with asthma contains elevated levels of various markers of oxidative stress [Baraldi et al. 2003; Corradi et al. 2001; Montuschi et al. 1999] ; and bromotyrosine and nitrotyrosine, also markers of oxidative stress have been found to be elevated in the airways of asthmatics [Kaminsky et al. 1999; Wu et al. 1999; Saleh et al. 1998 ]. Taken together, these data indicate that oxidative stress is enhanced in asthma, and that such redox imbalance is not confined within the lungs.
The inflammatory cells recruited to the asthmatic airways have an exceptional capacity for producing oxidants. Once recruited in the airspaces, inflammatory cells may become activated and generate reactive oxidants in response to various stimuli. Activated eosinophils, neutrophils, monocytes, and macrophages, and also resident cells such as bronchial epithelial cells, can generate oxidants [Henricks and Nijcamp, 2001; ]. Cluzel et al. [1987] investigated the respiratory burst of alveolar macrophages in BAL in subjects with asthma and healthy controls, which was significantly higher in asthmatic subjects, and there was a significant relation between ROS generation of alveolar macrophages and severity of asthma. Kelly et al. [1988] demonstrated that there was a twofold increase in generation of ROS from neutrophils asthmatic subjects compared with control subjects and fourfold from macrophages in asthmatic subjects compared with control subjects. Furthermore, macrophage ROS generation was associated with an increase in airway responsiveness.
Horvath et al. [1998] pointed out that eosinophils, which characteristically infiltrate asthmatic airways, produce very high levels of O 2 . À and NO and that these radicals interact, producing peroxynitrite, a highly reactive compound. H 2 O 2 is also produced by the dismutation of O 2 . À , and this can be measured in exhaled air as a measure of oxidative stress. Their investigation of NO and H 2 O 2 levels in exhaled air indicated that both H 2 O 2 and NO levels were elevated in steroid-naive asthmatic subjects compared with health subjects. These levels were reduced in stable steroid-treated asthmatic patients. There was also a correlation between expired H 2 O 2 , sputum eosinophils, and airway hyperresponsiveness [Horvath et al. 1998 ]. A recent study has confirmed this observation where exhaled breath condensate H 2 O 2 was negatively correlated with FEV 1 % predicted in asthmatic patients [Al-Obaidy and Al-Samarai, 2007] . Increased level of NO also appears to be a byproduct of airway inflammation and tissue damage and a possible indicator of oxidative stress in the airways [Ricciardolo et al. 2004] . High local concentration of NO along with superoxide anion has been found to have a cytotoxic effect on airway epithelial cells, which may contribute to epithelial cell shedding seen in asthmatic lungs [Heiss et al. 1994 ]. Damage to the epithelial cell layer can expose underlying sensory nerves to chronic irritants and inflammatory products, resulting in neuropeptide release and the induction of bronchoconstriction [Folkarts et al. 2001 ].
Since direct measurement of oxidants (such as superoxide and hydroxyl radicals and H 2 O 2 ) is often difficult due to their being highly reactive and short-lived; therefore oxidative stress is often measured by observing the damage inflicted by these oxidants upon various biomolecules, such as lipids, proteins or deoxyribonucleic acid. Recently, increased levels of many direct and indirect markers of oxidative stress (including superoxide, H 2 O 2 , malondialdehyde, thiobarbituric acid reactive products, isoprostanes) have been found in the urine, plasma, sputum, BAL fluid, and lung tissues of patients with asthma. These are footprints of oxidation on different substrates such as proteins (carbonyls, nitrotyrosine), lipids (isoprostanes, aldehydes, and ethane), and DNA (hydroxydeoxyguanosine) as shown in Table 1 . Their level is often related to the severity of the disease [Nadeem et al. 2003 ; Yamada et al. 2003; Saleh et al. 1998 ].
Saleh and coworkers [1998] reported strong immunoreactivity for nitrotyrosine (considered to be footprint of peroxynitrite mediated oxidative damage) in the airway epithelium and inflammatory cells in bronchial biopsies of patients with asthma, which was not seen in normal control subjects, and was reduced by inhaled corticosteroid treatment. In this study, the authors showed that the abundant expression of nitrotyrosine in asthmatic airways correlated with iNOS immunostaining and inversely with airway responsiveness to methacholine and pulmonary function [Saleh et al. 1998 ]. The stimuli that could be responsible for activation of iNOS and subsequent nitrotyrosine formation in these cells vary widely and include endogenous mediators (such as chemokines and cytokines) as well as exogenous factors such as bacterial toxins, virus infection, allergens, environmental pollutants and oxidants. It has also been demonstrated that exhaled nitrotyrosine was increased in patients with mild asthma who were not treated with corticosteroids and may be a sensitive marker to evaluate the contribution of nitrosative stress to airway inflammation in asthma [Hanazawa et al. 2000 ]. Another study demonstrated the presence of nitrotyrosine in the airways and lung parenchyma of patients with asthma who died of status asthmaticus supporting the concept that widespread airway and parenchymal oxidative stress may contribute in the pathophysiology of fatal asthma [Kaminsky et al. 1999] .
Eosinophils and neutrophils promote protein oxidative damage in both allergic asthma and severe asthma via the formation of reactive halogen species. It has been shown that bromotyrosine levels are an order of magnitude higher in proteins within BAL recovered from allergenchallenged segments of mild asthmatic subjects compared to either normal saline-challenged subsegments of asthmatics or allergen-challenged subsegments of nonasthmatic, nonatopic controls [Wu et al. 2000 ]. Strikingly, bromotyrosine levels in BAL proteins from subjects with severe asthma admitted to the intensive care unit with respiratory failure were elevated nearly 100-fold over nonasthmatic controls [MacPherson et al. 2001] . Recent studies by Kettle and colleagues confirm these observations, demonstrating significant increases in bromotyrosine content within induced sputum of asthmatics relative to nonasthmatic subjects [Aldridge et al. 2002] . Significant (two-to three-fold) elevations in chlorotyrosine have likewise been noted in proteins recovered from allergen-challenged subsegments from asthmatic subjects undergoing segmental allergen challenge [Wu et al. 2000] .
Another study has shown that in the bronchial tissues from individuals who died of asthma the most intense 3-nitrotyrosine immunostaining were in epitopes that colocalized with eosinophils suggesting a fundamental role for eosinophils as source of nitrating process in fatal asthma [MacPherson et al. 2001 ]. Using mice genetically deficient for EPO and an allergen challenge model of asthma, 70% of nitrotyrosine formed in the lungs of mice following allergen challenge is attributable to EPO, confirming a prominent role for EPO in nitrotyrosine formation [Brennan et al. 2002] .
Free radicals produced by inflammatory cells in the asthmatic lungs trigger lipid peroxidation chain reactions by abstracting a hydrogen atom from a side-chain methylene carbon. The resulting carbon-centered lipid radical then reacts with oxygen in aerobic cells to give a peroxyl radical that subsequently propagates a chain reaction, which transforms polyunsaturated fatty acids (either as free acids or as part of lipids) into lipid hydroperoxides. Schü nemann et al. [1997] analyzed the relation between respiratory function as measured by forced expiratory volume in 1st (FEV 1 ) with (a) levels of thiobarbaturic acid-reactive substances (TBARS) in plasma as indicators of lipid peroxidation and oxidative stress and in 132 nonsmoking adult subjects. There was a significant negative relation between FEV 1 % predicted and TBARS. The researchers concluded that increased lipid peroxidation in this general population sample was associated with respiratory airway narrowing [Schü nemann et al. 1997 ]. Studies by our lab and others have also shown increased TBARS in asthmatics as compared to control subjects [Jacobson et al. 2007; Ercan et al. 2006; Nadeem et al. 2003 ].
A recent study has also shown an inverse relationship of lipid peroxidation product, malodialdehyde in exhaled breath condensate with FVC and FEV 1 in asthmatic children [Romieu et al. 2008] . Isoprostanes that are generated by free radicals independently of cycloxygenase enzymes via the peroxidation of arachidonic acid have also been found to be elevated in plasma [Wood et al. 2000 ] and breath condensates [Montuschi et al. 1999 ] of asthmatics. Acute exacerbation of asthma has also been shown to increase levels of isoprostanes suggesting that lipid peroxidation and oxidative stress is further increased during acute inflammation [Wu et al. 2007 ]. Exhaled pentane levels, produced following peroxidation of n À 6 fatty acids, were no different from controls [Olopade et al. 1997 ]. Ethane, which is produced following lipid peroxidation of n À 3 fatty acids, has been reported to be higher in breath condensates of asthmatics [Paredi et al. 2000 ]. The peroxidation of membrane lipids may result in the change of membrane fluidity, disturbance in transmembrane ionic gradients and oxidative modification of proteins, which could lead to structural modification of proteins and increased susceptibility to proteolytic degradation [Droge, 2002; Davies, 1995] .
Taken together, these studies suggest that ROS production and subsequent oxidative stress in asthmatic airways may contribute to inflammatory injury, oxidative damage to the proteins and cell membranes, loss of elasticity, and other cumulative effects in the perpetual cycle of inflammation and repair.
Antioxidant defenses in the normal lung
The lung contains high levels of antioxidant resources to prevent oxidant-induced injury. Lung antioxidant defenses are widely distributed and include both enzymatic and non-enzymatic systems. The first and probably the most important line of defense against inhaled environmental oxidants and endogenous generated oxidants is a thin, highly-complex and heterogeneous layer of lining fluid, the respiratory-tract lining fluid (RTLF), that covers the respiratory epithelium. The RTLF has a unique composition of antioxidants, at a high concentration, including vitamin C, urate, reduced GSH, vitamin E and extracellular SOD, catalase, and GSH-Px. Additional antioxidants include mucopolypeptide glycoproteins, caeruloplasmin, Fe-binding proteins (e.g., lactoferrin and transferrin), and small molecules such as bilirubin [Avissar et al. 1996; Halliwell, 1996; Halliwell and Gutteridge, 1996; Heffner and Repine, 1989] .
Although nonenzymatic antioxidants are the first line of defense against different ROS, but several enzymatic antioxidants are needed to work in concert with nonenzymatic antioxidants to form a tightly regulated antioxidant network. Since superoxide radical is the primary oxidant produced from a variety of sources, its dismutation by SOD is of primary importance for each cell. There are three forms of SOD: (i) the copper-zinc superoxide dismutase (CuZn-SOD) is located in the cytosol, (ii) the manganese superoxide dismutase (Mn-SOD) is primarily a mitochondrial enzyme, and (iii) extracellular superoxide dismutase (EC-SOD) is usually found on the outside of the plasma membrane. All of them are widely expressed in human lung. CuZn-SOD, which is mainly a cytosolic enzyme, is evenly distributed intracellularly but is also found in the nucleus and lysosomes. It is expressed in the bronchial epithelium of human lung. Mn-SOD is localized to the mitochondria, a critical cell organelle both for cellular energy metabolism and cell survival. Mn-SOD is mainly expressed in alveolar type II epithelial cells and alveolar macrophages in the human lung. EC-SOD is primarily localized to the extracellular matrix, especially in areas containing high amounts of type I collagen fibers and around pulmonary and systemic vessels. It has also been detected in the bronchial epithelium, alveolar epithelium, and alveolar macrophages [Kinnula, 2005; Kinnula and Crapo, 2003 ].
Overall, CuZn-SOD and Mn-SOD are generally thought to act as bulk scavengers of superoxide radicals. However, the relatively high EC-SOD level in the lung with its specific binding to the extracellular matrix components may represent a fundamental component of lung matrix protection [Zelko et al. 2002] .
H 2 O 2 that results from the action of SODs (or the action of oxidases, such as xanthine oxidase) is reduced to water by catalase and the GSH-Pxs. Catalase exists, as a tetramer comprised of four identical monomers that each contain a heme group at the active site. Degradation of H 2 O 2 is accomplished via a conversion between two conformations of catalase: ferricatalase (iron coordinated to water) and compound I (iron complexed with an oxygen atom). Catalase also binds NADPH as a reducing equivalent to prevent oxidative inactivation of the enzyme (formation of compound II) by H 2 O 2 as it is reduced to water [Kirkman et al. 1999] .
Enzymes in the redox cycle responsible for the reduction of H 2 O 2 as well as lipid hydroperoxides (generated as result of membrane lipid peroxidation) include the GSH-Px [Flohe, 1989] . The GSH-Pxs, a family of tetrameric enzymes contain the unique amino acid selenocysteine within their active sites and use low-molecular-weight thiols such as GSH to reduce H 2 O 2 and lipid peroxides to their corresponding alcohols. Four GSH-Pxs have been described, encoded by different genes: GSH-Px-1 (cellular GSH-Px) is ubiquitous and reduces H 2 O 2 as well as fatty acid peroxides, but not esterified peroxyl lipids [Arthur, 2000] . Esterified lipids are reduced by membranebound GSH-Px-4 (phospholipid hydroperoxide GSH-Px), which can use several different lowmolecular-weight thiols as reducing equivalents [Brigelius-Flohe et al. 1994 ]. GSH-Px-2 (gastrointestinal GSH-Px) is localized in gastrointestinal epithelial cells, where it serves to reduce dietary peroxides [Chu et al. 1993 ]. GSH-Px-3 (extracellular GSH-Px) is the only member of the GSH-Px family that resides in the extracellular compartment and is believed to be one of most of important extracellular antioxidant enzyme in mammals. It was first identified as a distinct enzyme in human plasma [Takahashi et al. 1987] . Of these, extracellular GSH-Px has been most widely investigated in human lung ].
In addition, disposal of H 2 O 2 is closely associated with several thiol-containing proteins-namely, thioredoxins (TRX1 and TRX2), thioredoxin reductases (TRR), peroxiredoxins (PRX) (which are thioredoxin peroxidases), and glutaredoxins [Gromer et al. 2004; Holmgren, 2002] . All these enzymes are considered to be powerful redox modulators; they also have antioxidant properties, protect cells against high oxygen tension, and participate in cell proliferation and survival. Two TRXs and TRRs have been characterized in human cells, existing in both cytosol and mitochondria. In human lung, TRX and TRR are expressed in bronchial and alveolar epithelium and macrophages. Six different PRXs have been found in human cells, differing in their ultrastructural compartmentalization. Experimental studies have revealed the importance of PRX VI in the protection of alveolar epithelium. Human lung expresses all PRXs in bronchial epithelium, alveolar epithelium, and macrophages [Kinnula et al. 2002] . PRX V has recently been found to function as a peroxynitrite reductase [Dubuisson et al. 2004] , which means that it may function as a potential protective compound in the development of ROS-mediated lung injury [Holmgren, 2000] .
Common to these antioxidants is the requirement of NADPH as a reducing equivalent.
NADPH maintains catalase in the active form and is used as a cofactor by thioredoxin as well as GSH reductase, which converts oxidized glutathione (GSSG) to GSH, a cosubstrate for the GSH-Pxs. Intracellular NADPH, in turn, is generated by the reduction of NADP þ by glucose-6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme of the pentose phosphate pathway, during the conversion of glucose-6-phosphate to 6-phosphogluconolactone. By generating NADPH, G6PD is a critical determinant of cytosolic GSH buffering capacity (GSH/GSSG), and therefore, can be considered an essential, regulatory antioxidant enzyme [Dickinson and Forman, 2002; Sies, 1999; Chance et al. 1979 ].
In the normal lung, therefore, complex and coordinated interactions of nonenzymatic as well as enzymatic antioxidant compounds provide adequate protection to different lung structures from the damaging effects of oxidative attack as shown in Figure 1 .
Imbalance of antioxidant defenses in asthma
Mammals have evolved complex antioxidant strategies (enzymatic/nonenzymatic) to utilize oxygen and to minimize the noxious effects of reactive oxygen species (Table 2) . Antioxidants within cells, cell membranes, and extracellular fluids can be upregulated and mobilized to neutralize excessive and inappropriate ROS formation [Halliwell and Gutteridge, 1996] . The extent of oxidative stress will depend in part on the antioxidant defenses available within the RTLF. Any deficiencies in this compartment will compound the ROS-mediated airway responses and tissue injury.
Evidence for an oxidant-antioxidant imbalance in asthmatic airways is provided by the findings that show decreased total antioxidant capacity as well as individual antioxidants in plasma and BAL fluid of patients with asthma [Nadeem et al. 2003; Kanazawa et al. 2002; Comhair et al. 2000; De Raeve et al. 1997 ]. Deficiencies in individual nonenzymatic antioxidants have been frequently reported in asthmatics. Low levels of vitamin C and urate in the RTLF have been observed in adults with mild asthma, together with increased amounts of GSSG in their airways [Kelly et al. 1999] . Vitamin C has been found to be decreased in plasma/ serum [Kalayci et al. 2000; Vural and Uzan, 2000; Aderele et al. 1985] , whole blood [Shanmugasundaram et al. 2001 ] and BAL fluid [Kelly et al.1999] by several workers. Vitamin E has also found to be decreased in BAL fluid [Kelly et al.1999] , bronchial wash [Kelly et al.1999] , red cells [Mohan and Das, 1997] and plasma [Shanmugasundaram et al. 2001; Kalayci et al. 2000; ] . Beta-carotene is reported to be low in serum [Kalayci et al. 2000 ]. Bilirubin, another antioxidant has also reported to be low in asthmatics [Misso et al. 2005] . Disturbed GSH status is reported in asthma, ) are produced in several cell compartments such as mitochondria, cytosol, and cell membrane (in both phagocytic and nonphagocytic cells). O 2 . À is dismutated to H 2 O 2 by SOD, which are highly expressed in each cell. The production of H 2 O 2 is balanced by the high constitutive levels of different antioxidants, such as GSH-Px and catalase. In addition, there are several nonenzymatic antioxidants such as reduced GSH, vitamin E, bilirubin, vitamin C, carotenoids, thioredoxin, and uric acid, which can directly scavenge different ROS including H 2 O 2 and O 2 . À . Therefore, there is little or no oxidative stress during normal metabolism of healthy lung. In this scenario, O 2 . À mediated attack on NO produced by eNOS/nNOS is spared due to the presence of high constitutive SOD activity that helps in maintaining normal bronchomotor tone in the airways. with total [Smith et al. 1993 ] and oxidized GSH being elevated in BAL fluid [Kelly et al.1999] and reduced GSH and total GSH being elevated in red cells [Nadeem et al. 2003; Vural and Uzan, 2000] . In a study by Wood et al. [2005] , whole blood carotenoids levels (lycopene, lutein, alphacarotene, and beta-carotene) have reported to be lower in asthmatics as compared to controls. Wood et al. [2008a] have shown recently that plasma alpha-tocopherol was low and sputum supernatant levels of total, reduced, and oxidized GSH were elevated in asthma vs controls. In a most recent study, Sackeson et al. [2008] have also reported decreased levels of most of the nonenzymatic antioxidants (i.e., vitamin C, vitamin E, reduced GSH, lycopene, and carotenoids) in asthmatic children.
The co-operation among different antioxidants provides greater protection against attack by ROS, than any compound alone. Thus, overall antioxidant capacity of the cell/tissue may give more biologically relevant information than that obtained from measuring individual antioxidants. Moreover, this AC is the result of tightly regulated antioxidant network among different antioxidants and may be modulated either by radical overload or by the intake of dietary antioxidants/ compounds, and can therefore be regarded as more representative of the in vivo balance between oxidizing species and antioxidant compounds than the concentration of single, selected antioxidants [Ghiselli et al. 2000; Chaudiere and Ferrari-Illiou, 1999] . Rahman et al. [1996] evaluated the imbalance between oxidants and antioxidants in the plasma of smokers and asthmatic patients with healthy nonsmokers by comparing the Trolox equivalent antioxidant capacity (TEAC) and products of lipid peroxidation as indices of oxidative stress. The plasma TEAC was markedly reduced in patients presenting with acute exacerbations of asthma compared with healthy nonsmokers, and plasma TEAC was somewhat less reduced in subjects with stable asthma. Katsoulis et al. [2003] also reported decreased TEAC in acute exacerbation of asthma as compared to stable asthmatics, which was correlated with FEV 1 . Peroxynitrite inhibitory activity in sputum, which is reflection of total antioxidants, is also reported to be low in asthmatics as compared to normal controls. Moreover, Peroxynitrite inhibitory activity was also correlated with the degree of airway obstruction and airway hyperreactivity to methacholine. A significant negative correlation between peroxynitrite inhibitory activity in induced sputum and the degree of eosinophilic airway inflammation was also found in this study [Kanazawa et al. 2002] . This work suggested that elevated total antioxidant capacity could help counter the oxidative stress of asthma and possibly contribute to an amelioration of asthmatic symptomatology. Our studies have also confirmed this view where plasma total antioxidant capacity was directly correlated with severity of the disease as well as FEV 1 % predicted in asthmatics [Nadeem et al. 2005 [Nadeem et al. , 2003 ].
Further evidence of oxidant-antioxidant imbalance is provided by studies that show alteration in key enzymatic antioxidants in blood and lung in patients with asthma. SOD activity has been reported to be increased [Kurosawa et al. 1993] , decreased [Shanmugasundaram et al. 2001; Comhair et al. 2000; Tekin et al. 2000; De Reave et al. 1997; Smith et al. 1997] or unchanged [Wood et al. 2000; Mohan and Das, 1997; Powell et al. 1994; Smith et al. 1993; Novak et al. 1991] in asthmatics as compared to controls. Similarly, GSH-Px activity has been reported to be decreased [Nadeem et al. 2003; Shanmugasundaram et al. 2001; Bibi et al. 1988; Mohan and Das, 1997; Powell et al. 1994] or unchanged [Tekin et al. 2000; Wood et al. 2000; De Reave et al. 1997; Misso et al. 1996] in asthmatics. Catalase, another, antioxidant enzyme, has also been reported to have low activity [Shanmugasundaram et al. 2001; Novak et al.1991] or unchanged [Nadeem et al. 2003; Tekin et al. 2000; De Reave et al. 1997; Mohan and Das, 1997; Smith et al. 1997; ] . Paraoxonase, another enzymatic antioxidant responsible for protection of low and highdensity lipoproteins against ROS-mediated attack was also found to be lower in plasma of asthmatic patients [Ekmekci et al. 2006 ]. Many studies do not find any difference in enzymatic activities in asthmatics when compared with controls. It may be because plasma antioxidants are first line of defense against ROS-mediated attack. The enzymatic antioxidants may come into play when first line is overwhelmed. Moreover, most of the studies are carried out with only a single time measurement, differences might occur later in time that requires serial observations in the patients. While the data are difficult to compare due to differences in disease severity, blood components and body fluids being measured, it is clear that overall status of antioxidant enzymes is often altered in asthma indicating a disturbed oxidantantioxidant balance.
Since many studies have shown associations between airway obstruction/severity of the disease and systemic oxidant-antioxidant imbalance (Table 3) ; it suggests that blood has a central role because it transports and redistributes antioxidants to every part of the body to maintain redox balance against oxidant conditions, e.g. chronic inflammation [Evans and Halliwell, 2001; Davies, 1995; Halliwell and Cross, 1994] . For example, plasma can scavenge ROS, such as the superoxide anion or hydrogen peroxide produced by leukocytes, thus preventing reactions with catalytic metal ions to produce more harmful species [Mao and Poznansky, 1992; Lynch and Fridovich, 1978] . It can also reduce oxidized ascorbic acid back to ascorbate [Wagner et al. 1987; Okamura et al. 1979] . Red cells may also play an important role in oxidant-induced lung damage by supplying their antioxidants to the lung, thereby augmenting lung antioxidant capacity. Red cells are considered to be important reservoirs of antioxidants such as SOD, catalase, GSH-Px and GSH [Winterbourn and Stern, 1987; Van Asbeck et al. 1985; Toth et al. 1984] . Additionally, red cells contain an anion channel through which the poorly diffusible superoxide anion can travel, thereby becoming available for the dismutation by red cell SOD [Lynch and Fridovich, 1978] . The capacity of red cells to metabolize extracellular ROS has been demonstrated by Winterbourn and Stern [1987] , who observed an immense rate of hydrogen peroxide reduction by red cells in vitro. Red cells exposed to oxidants also adhere more to endothelial surface [Wali et al. 1987] , which may buffer the surrounding tissue like lung and may act as sink in the pulmonary microcirculation for excess of O 2 . À and H 2 O 2 and other forms of ROS in case of increased oxidative stress and provide the lung important antioxidant protection. Hence, blood oxidant-antioxidant status is the result of the interaction of many different enzymatic and nonenzymatic systems and systemic metabolic interactions and may reflect the changes taking place in the lung.
Taken together, these data clearly indicate that airway oxidant-antioxidant imbalance, probably as a consequence of the inflammatory response, could play an important role in the development of asthmatic symptomatology and possibly in the etiology of asthma (Figure 2 ).
Observational studies with dietary antioxidants in asthma
The prevalence of asthma has increased considerably in many countries over recent decades, suggesting that environmental factors especially diet may play a dominant role in the etiology of the disease [McKeever and . Seaton et al. [1994] have proposed that individuals in westernized societies have progressively reduced their consumption of fruit and vegetables, and as a result have decreased pulmonary antioxidant defences, making them more susceptible to inhaled irritants and allergens. Various enzymatic, dietary, and high-molecular-weight antioxidant systems could defend against oxidative stress/antioxidant deficiency in asthmatic airways. As many antioxidants are supplied from the diet, attention has been paid to intake of the micronutrient antioxidants (vitamins A, C, and E, polyphenols and carotenoids), and how it may help to protect individuals from an oxidizing environment and/or inflammatory airways disease.
Vitamin C Water-soluble vitamin C provides intracellular and extracellular aqueous-phase antioxidant capacity primarily by scavenging oxygen free radicals. In general, most studies of dietary vitamin C have reported beneficial associations with ventilatory function, a smaller number have reported associations with asthma, and very few, if any, have shown associations with atopic disease.
Epidemiologic studies done so far have demonstrated that dietary vitamin C intake or serum ascorbate is positively associated with ventilatory function in children and adults [Gilliland et al. 2003; Hu and Cassano, 2000; Britton et al. 1995; Schwartz and Weiss, 1994] . In the First National Health and Nutrition Examination Survey (NHANES I) dietary vitamin C intake was positively associated with FEV 1 in adults, with a mean 40 mL FEV 1 difference between subjects with the highest and lowest tertiles of vitamin C intake [Schwartz and Weiss, 1994] . In NHANES III serum, but not dietary, vitamin C was positively associated with FEV 1 in a crosssectional adult study [Hu and Cassano, 2000] . Dietary vitamin C has been less frequently associated with asthma and wheezing symptoms in children and adults [Rubin et al. 2004; Harik-Khan et al. 2004; Bodner et al. 1999; Soutar et al. 1997 ]. In a nested case-control study of adults, serum ascorbate was negatively associated with adult-onset wheeze; with an SD increase in serum ascorbate being associated with a 40% reduction in adult onset wheeze [Bodner et al. 1999] . Misso et al. [2005] reported that low plasma vitamin C levels were independently associated with severe asthma. In a case-control study dietary vitamin C intake was negatively associated with the likelihood of methacholine airway reactivity in adults [Soutar et al. 1997] .
Vitamin E Lipid-soluble vitamin E is the principal defense against oxidant-induced membrane injury. 
Epithelial cells
Airway smooth muscle Figure 2 . Inflammatory cells such as eosinophils, monocytes, lymphocytes, and neutrophils recruited to the lung generate both O 2 . À and NO during asthmatic inflammation. Most of the oxidants in these inflammatory cells are produced through activation of NADPH oxidase on cell membranes, iNOS, MPO, and EPO. Increased oxidative stress leads to altered homeostasis, and NO-mediated bronchorelaxation is disrupted with conversion of NO to proinflammatory and cytotoxic species such as peroxynitrite (ONOO À ). H 2 O 2 and O 2 . À contribute to increased oxidative stress directly by depleting/altering several key antioxidants (enzymatic/ nonenzymatic) and causing LPO as well as through EPO and MPO catalyzed oxidative reactions forming HOCl and HOBr acid in the asthmatic lung. These oxidative events cause alteration in protein structure, membrane integrity, and cellular function leading to pathophysiological effects associated with asthmatic airways.
In contrast to vitamin C, it also has nonantioxidant effects on immune function that might account for differences in its epidemiologic associations. Studies have consistently demonstrated beneficial associations between dietary vitamin E and ventilatory function [Gilliland et al. 2003; Schü nemann et al. 2001; Butland et al. 2000; Hu and Cassano, 2000] and a few others have demonstrated beneficial associations with asthma and atopy [Fogarty et al. 2000; Hijazi et al. 2000; Bodner et al. 1999; Troisi et al. 1995] .
In a cross-sectional study of children aged 11-19 years, dietary vitamin E intake was positively associated with ventilatory function [Gilliland et al. 2003 ]. These associations were more marked in boys, with dietary vitamin E intakes in the lowest decile being associated with reduced FEV 25-75 , and FEV 1 /forced vital capacity ratio when compared with intakes greater than the lowest decile. The Caerphilly study carried out in cohort of 2512 middle aged men reported that dietary vitamin E intake was positively associated with FEV 1 in a cross-sectional analysis. A 5-year longitudinal analysis indicated that the protective effect of vitamin E was not reversible because there was no significant association between change in FEV 1 over a 5-year period and change in dietary vitamin E intake or averaged dietary vitamin E intake [Butland et al. 2001] . Dietary vitamin E intake was negatively associated with asthma and wheezing in a casecontrol study of 12-year-old Saudi Arabian children [Hijazi et al. 2000 ]. Dietary and serum vitamin E have been negatively associated with adult-onset wheeze [Bodner et al. 1999] . The US Nurses' Health Study reported that the incidence of physician-diagnosed asthma over a 10-year period was negatively associated with dietary intake of vitamin E [Troisi et al. 1995] . The highest quintile of intake was associated with a 47% reduction in the likelihood of asthma development when compared with the lowest quintile. In adults a negative association has been demonstrated between dietary vitamin E intake and serum IgE levels and the likelihood of atopic sensitization [Fogarty et al. 2000 ].
Vitamin A Vitamin A was the first fat-soluble vitamin identified with three activity forms: retinol, retinal, and retinoic acid, which collectively are called retinoids. In addition, there are 600 provitamin A compounds, many of which (-carotene, -cryptoxanthin, lutein-zeaxanthin, and lycopene) have strong antioxidant activity. Although retinol is not usually considered to be an antioxidant, it has been implicated in normal respiratory epithelial development and lung development. Beneficial associations have been demonstrated between dietary carotenoids and ventilatory function, diagnosed asthma, and respiratory symptoms [Harik-Khan et al. 2004; Rubin et al. 2004; Gilliland et al. 2003; Hu and Cassano, 2000; Schü nemann et al. 2001] . Two analyses of NHANES III data from children aged 4-17 years demonstrated negative associations between asthma and serum levels of -carotene [Harik-Khan et al. 2004] and -carotene [Rubin et al. 2004] . SD increases in serum -carotene and -carotene levels were associated with 13% and 20% reductions in asthma prevalence, respectively. Dietary and serum -carotene levels were positively associated with FEV 1 in adults participating in NHANES III [Hu and Cassano, 2000] ). Recently, Riccioni et al. [2007] found in PLAVA study that serum lycopene and vitamin A concentration was significantly lower in asthmatic subjects than in healthy control subjects.
Antioxidant intervention studies
The epidemiologic studies discussed above suggest that there are beneficial associations between asthma/atopic disease and dietary antioxidants, such as vitamin C, vitamin E, some carotenoids, and antioxidant-rich fruits. There have been many intervention studies, the majority of which have supplemented with vitamin C [Tecklenburg et al. 2007; Fogarty et al. 2003 Fogarty et al. , 2006 and E [Pearson et al. 2004 ] and carotenoids [Neuman et al. 1999 [Neuman et al. , 2000 Wood et al., 2008b] . In general, the results of these supplementation studies have not been too convincing, with a few studies reporting beneficial effects especially in exercise-induced asthma (Table 4) .
One postulated reason for the ineffectiveness of intervention is that antioxidant supplementation is only effective when there is a marked antioxidant deficiency or increased oxidative stress due to additional factors such as exercise/ozone on top of asthmatic inflammation. That is why most of the beneficial effects in intervention trials have been observed only after exercise or ozone exposure in asthmatics [Romieu et al. 2002; Sienra-Monge et al. 2004; Trenga et al. 2001] .
Other reason could be due to the role of the antioxidant micronutrients, e.g. carotenoids and vitamin E [Stahl et al. 2002; Azzi and Stocker, 2000; Brigelius-Flohe and Traber, 1999] as nonantioxidant molecules. These micronutrients could therefore mediate functions seemingly unrelated to their actions on redox potential, including pathways related to immunomodulation and gene expression. The nonantioxidant properties of antioxidant micronutrients pertinent to asthma and atopic disease could be exerted early in the childhood/prenatal period through immune cells that play pivotal roles in the initiation and perpetuation of the chronic inflammatory process. These effects are difficult to determine due to the complex interactions of various antioxidants and time period/sample size required to complete these studies.
Antioxidants with possible therapeutic potential in asthma If ROS participate in the inflammatory response in airway disease, then radical scavengers or antioxidants could play a useful role in therapy because anti-oxidants can mobilize and upregulate the antioxidative capacity of cells to annihilate excessive ROS formation. This can be achieved through two approaches; either by increasing the endogenous antioxidant enzyme defenses or by enhancing the nonenzymatic defenses through dietary or pharmacological supplementation.
Evidence in support of the concept that antioxidants might influence asthmatic pathobiology is that: T-helper 1 and 2 cytokines are differentially regulated under conditions of oxidative stress [Malmberg et al. 2001] ; apoptotic death pathways, which are activated in the respiratory tract epithelia cells of subjects with asthma and are important in the clearance of airway phagocytes [Vignola et al. 2000] , are known to be modulated by antioxidants [Droge, 2002] ; antioxidants may decrease phagocyte and nonphagocyte NADPH oxidase activities [Halliwell, 2000] .
Thiols
In the pulmonary system, thiols in the form of GSH (reduced GSH) and sulfhydryl groups attached to several proteins constitute one of the main antioxidant defenses both intracellularly Therapeutic Advances in Respiratory Disease and extracellularly since they are considered to be the prime redox regulator of cell environment [Schafer and Buettner, 2001; Chaudiere and Ferrari-Illiou, 1999] . Unfortunately, inhalation of GSH into the lung is characterized by a poor half-life [Borok et al. 1991] and airway hyper reactivity . Moreover, intracellular antioxidant protection after GSH administration is also restricted due to its inefficient cellular uptake [MacNee and , which has led to augmenting GSH levels through the use of N-acetylcysteine (NAC), a GSH precursor [MacNee et al. 1991 ]. However, NAC has the disadvantage of being acidic in the solution.
An alternative approach is the use of lysine salt of NAC, N-acystelyn (NAL). It also possesses antioxidant properties leading to reduction of both ROS levels and ROS-mediated inflammatory events in vitro [Antonicelli et al. 2002] . NAL has also been shown to possess anti-inflammatory properties in vivo through reduction of LPSinduced neutrophilic inflammation [Antonicelli et al. 2004 ]. NAL has several advantages over NAC; firstly, it can augment GSH levels twice as effectively as NAC and secondly it forms a neutral pH when in solution, unlike N-acetylcysteine that is acidic [Gillissen et al. 1997 ]. This has meant that when delivered directly into the lung by aerosol in healthy volunteers, it did not cause any irritation or other side effects [App et al. 2002] . Therefore, NAL may be more promising than NAC in reducing the oxidant burden in the asthmatic airways. Another thiol compound, N-acetylcysteine amide has been shown to reduce airway inflammation and hyperresposiveness by increasing GSH and reducing ROS in allergic mice [Lee et al. 2007a] .
The potential role of other thiols as antioxidants is also being explored in several other studies. One of these is a naturally occurring intracellular aromatic thiol, ergothioneine present both in plants and animals [Hand et al. 2005] . It possesses antioxidant activity, especially for prevention of peroxynitrite-dependent oxidative damage to proteins [Aruoma et al. 1997 ]. However, with the recent discovery of a membrane transporter for this compound [Grundemann et al. 2005] , ergothioneine could be a useful too for boosting intracellular antioxidants defenses. Most recently, Sareila et al. [2008] have reported beneficial anti-inflammatory effects of a sulfhydrylmodulating compound, Orazipone in experimental model of asthma. Another strategy of increasing cellular GSH has involved the use of gamma-glutamylcysteinylethyl ester, a precursor for GSH synthesis. This strategy has proved useful in attenuation of airway inflammation and hyperresposiveness in allergic mouse model of asthma [Koike et al. 2007 ]. All these thiol compounds are good prospects for use as antioxidants in clinical trials but are yet to be tested in asthmatic patients for efficacy.
Redox sensor inhibitors
The intracellular redox status of the cell is not only affected by the external environment but also by the contribution of internal redox couples such as NADP/NADPH and GSH/GSSG. The relative contribution of each reduced vs oxidized isoform of these couples can in turn affect the overall redox state of the cell. GSH being the most abundant redox sensor plays an important protective function as described above. The NADP/NADPH system can also play a protective role, particularly in the mitochondrial compartment, buffering against excessive redox imbalance. Recently, the oxidoreductase family of redox sensors, such as thioredoxin and redox effector factor-1 (ref-1), has attracted attention in several studies. Thioredoxin, has been reported to play an important role in regulation of redox-sensitive signaling pathways, such as nuclear factor-kappaB (NF-kB) and activator protein-1 (AP-1), p38 mitogen-activated protein kinases (MAPK), and c-jun N-terminal kinase (JNK) [Filomeni et al. 2002] .
Thioredoxin has been reported to associate with the apoptosis signal regulating kinase, ASK-1 [Saitoh et al. 1998 ], as heterodimeric complexes. Under conditions of oxidative stress, thioredoxin is released from these complexes liberating ASK-1 [Filomeni et al. 2002] with the net result being activation of p65 NF-kB subunit [Qin et al. 1995] . Concurrently, the free ASK-1 is also activated by oxidative stress leading to activation of the pro-inflammatory p38MAPK and JNK pathways [Filomeni et al. 2002] , which are also known to be redox sensitive. By inhibiting the oxidoreductase activity of thioredoxin with the small molecular weight inhibitor MOL-294, it has been shown that both NF-kB-and AP-1-dependent transcriptional activity is inhibited [Henderson et al. 2002] . A different redox sensor inhibitor, PNRI-299, has also been shown to prevent AP-1 activation, which is achieved through inhibition of another oxidoreductase family member similar to thioredoxin, namely, ref-1 [Nguyen et al. 2003 ]. Both inhibitors have been shown to reduce airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and pro-inflammatory cytokine release in vivo in a murine model of asthma [Nguyen et al. 2003; Henderson et al. 2002] . It remains to be seen whether these redox sensor inhibitors are also useful therapeutically in human asthmatics.
Enzyme mimetics
Enzyme mimetics are usually small compounds that possess catalytic activity that mimics the activity of larger enzyme-based molecules such as the SOD, catalase, and GSH-Px like activities. Synthetic SOD mimetics have been developed to avoid the problems associated with endogenous antioxidant enzymes such as high immunogenity and to improve their penetration capability and efficacy [Kinnula, 2005] . Enzyme mimetics have been shown to have at least four propertiesnamely, scavenging of superoxide, H 2 O 2 , peroxynitrite, and lipid peroxides. A number of SOD mimetics based around organo-manganese complexes have been developed, which retain their antioxidant properties in vivo. These consist of a series of the manganese-metaloporphyrinbased compounds as exemplified by AEOL-10113 and AEOL-10150 [Chang and Crapo, 2002] . The second class of SOD mimetics are a series of manganese-based macrocyclic ligands, such as M40401, M40403, and M40419 [Tuder et al. 2003; Salvemini et al. 1999] . The third class of manganese-based SOD mimetic is the 'Salens'. These are generally aromatic substituted ethylenediamine-metal complexes [Doctrow et al. 1997 ]. An example being EUK134 [Chatterjee et al. 2004; Izumi et al. 2002] .
AEOL10150 and AEOL10113 have been studied in models of airway inflammation. In one study, AEOL10113 was shown to inhibit both airway inflammation and bronchial hyperreactivity in an ovalbumin challenge model of airway inflammation [Chang and Crapo, 2002] . Another type of catalytic antioxidant is the GSH-Px mimetic Ebselen. This is a selenium-based organic complex and has been shown to be a very powerful antioxidant against several ROS such as singlet oxygen, hypochlorous acid and the peroxynitrite radical [Jozsef and Filep, 2003] . It is able to prevent both NF-kB/AP-1 activation and pro-inflammatory gene expression in human leukocytes exposed to peroxynitrite. Other studies have shown that Ebselen is also active in vivo in preventing LPS-induced airway inflammation [Haddad et al. 2002; Zhang et al. 2002] . These studies highlight the importance of these compounds in preventing oxidant-induced damage and potential use as future therapeutic compounds.
Polyphenols
Numerous epidemiological have established a beneficial link between polyphenol intake and lower disease risk with the beneficial clinical outcomes being attributed to both the antioxidant and anti-inflammatory properties of polyphenols [Arts and Hollman, 2005] . One Finnish study with around 10,000 participants has shown a significant inverse correlation between polyphenol intake and the incidence of asthma [Knekt et al. 2002] . Polyphenols consist of a large group of natural antioxidants usually extracted from plants. Chemically, several different classes of polyphenol exist, such as the benzoic acids, cinnamic acids, coumarins, gallotannins, and flavonoids with one or more aromatic rings along with at least one hydroxyl group thought to be responsible for antioxidant functions.
Several studies have showed a direct impact of specific polyphenolic compounds on inflammation in vitro and in vivo. For example, gallotannins in a recent study have been shown to suppress pro-inflammatory cytokines and NF-kB activation in human mast cells [Lee et al. 2007b ]. Birrell et al. [2005] have demonstrated that resveratrol can inhibit inflammatory cytokine expression in response to LPS challenge in rat lungs in vivo. Moreover, in both monocytic U937 cells and airway epithelial A549 cells, resveratrol inhibits NF-kB and AP-1 activation [Donnelly et al. 2004; Manna et al. 2000 ]. The mechanism through which these effects occur is still unclear. Due to the antioxidant properties of resveratrol and other polyphenols, it is possible that they may interact with redox sensitive pathways thereby preventing activation of genes that regulate inflammation.
Concluding remarks
Asthmatic inflammation is characterized by ongoing inflammation and accompanied by increased oxidative stress and subsequent lung injury. ROS generation through endogenous mechanisms or exogenous environmental exposure is critical to the inflammatory response through perpetuation and amplification of pro-inflammatory signaling pathways. At the same time, endogenous antioxidant mechanisms are present to counteratc this ROS-mediated inflammatory response. It is when these two opposing mechanisms are out of balance that a chronic inflammatory state emerges. Modulation of these events by enhancing antioxidant levels offers unique opportunities for therapeutic prevention or inhibition of inflammation. Before this approach a becomes reality, additional research is needed to better understand not only the molecular events involved in the pathogenesis of asthmatic inflammation, but also the complex actions and interplay between antioxidants and ROS in both the healthy and the asthmatic lung.
A better understanding of these issues would provide useful information in designing more appropriate antioxidant-based treatments and intervention trials in the future. These trials could be successful only if they show that supplemented antioxidant can: (i) be effectively delivered (bioavailable) to the sites of inflammation in the lung; (b) prevent deleterious oxidations; and (c) most importantly, be useful in the prevention and/or treatment of the clinical manifestations of asthma.
